These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37990249)

  • 21. Interleukin-6 blocking agents for treating COVID-19: a living systematic review.
    Ghosn L; Chaimani A; Evrenoglou T; Davidson M; Graña C; Schmucker C; Bollig C; Henschke N; Sguassero Y; Nejstgaard CH; Menon S; Nguyen TV; Ferrand G; Kapp P; Riveros C; Ávila C; Devane D; Meerpohl JJ; Rada G; Hróbjartsson A; Grasselli G; Tovey D; Ravaud P; Boutron I
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013881. PubMed ID: 33734435
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial.
    Wolfe CR; Tomashek KM; Patterson TF; Gomez CA; Marconi VC; Jain MK; Yang OO; Paules CI; Palacios GMR; Grossberg R; Harkins MS; Mularski RA; Erdmann N; Sandkovsky U; Almasri E; Pineda JR; Dretler AW; de Castilla DL; Branche AR; Park PK; Mehta AK; Short WR; McLellan SLF; Kline S; Iovine NM; El Sahly HM; Doernberg SB; Oh MD; Huprikar N; Hohmann E; Kelley CF; Holodniy M; Kim ES; Sweeney DA; Finberg RW; Grimes KA; Maves RC; Ko ER; Engemann JJ; Taylor BS; Ponce PO; Larson L; Melendez DP; Seibert AM; Rouphael NG; Strebe J; Clark JL; Julian KG; de Leon AP; Cardoso A; de Bono S; Atmar RL; Ganesan A; Ferreira JL; Green M; Makowski M; Bonnett T; Beresnev T; Ghazaryan V; Dempsey W; Nayak SU; Dodd LE; Beigel JH; Kalil AC;
    Lancet Respir Med; 2022 Sep; 10(9):888-899. PubMed ID: 35617986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Janus kinase inhibitors for the treatment of COVID-19.
    Kramer A; Prinz C; Fichtner F; Fischer AL; Thieme V; Grundeis F; Spagl M; Seeber C; Piechotta V; Metzendorf MI; Golinski M; Moerer O; Stephani C; Mikolajewska A; Kluge S; Stegemann M; Laudi S; Skoetz N
    Cochrane Database Syst Rev; 2022 Jun; 6(6):CD015209. PubMed ID: 35695334
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of current medications for treating severe and non-severe COVID-19 patients: an updated network meta-analysis of randomized placebo-controlled trials.
    Cheng Q; Chen J; Jia Q; Fang Z; Zhao G
    Aging (Albany NY); 2021 Sep; 13(18):21866-21902. PubMed ID: 34531332
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-Effectiveness of Baricitinib Compared With Standard of Care: A Modeling Study in Hospitalized Patients With COVID-19 in the United States.
    Ohsfeldt R; Kelton K; Klein T; Belger M; Mc Collam PL; Spiro T; Burge R; Ahuja N
    Clin Ther; 2021 Nov; 43(11):1877-1893.e4. PubMed ID: 34732289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.
    Singh B; Ryan H; Kredo T; Chaplin M; Fletcher T
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD013587. PubMed ID: 33624299
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety of Tofacitinib, Baricitinib, and Upadacitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
    Wang F; Sun L; Wang S; Davis JM; Matteson EL; Murad MH; Luo F; Vassallo R
    Mayo Clin Proc; 2020 Jul; 95(7):1404-1419. PubMed ID: 32499126
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of different doses of baricitinib for rheumatoid arthritis: A Bayesian network meta-analysis.
    Haikun W; Na W; Dan S
    Medicine (Baltimore); 2022 Sep; 101(38):e30676. PubMed ID: 36197174
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk of Venous Thromboembolism Associated With Tofacitinib and Baricitinib: A Systematic Review and Indirect Meta-Analysis.
    Giménez Poderós T; Gallardo Borge S; Vazquez-Ferreiro P
    Pharmacotherapy; 2020 Dec; 40(12):1248-1264. PubMed ID: 33064892
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anticoagulants for people hospitalised with COVID-19.
    Flumignan RL; Civile VT; Tinôco JDS; Pascoal PI; Areias LL; Matar CF; Tendal B; Trevisani VF; Atallah ÁN; Nakano LC
    Cochrane Database Syst Rev; 2022 Mar; 3(3):CD013739. PubMed ID: 35244208
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interleukin-6 blocking agents for treating COVID-19: a living systematic review.
    Ghosn L; Assi R; Evrenoglou T; Buckley BS; Henschke N; Probyn K; Riveros C; Davidson M; Graña C; Bonnet H; Jarde A; Ávila C; Nejstgaard CH; Menon S; Ferrand G; Kapp P; Breuer C; Schmucker C; Sguassero Y; Nguyen TV; Devane D; Meerpohl JJ; Rada G; Hróbjartsson A; Grasselli G; Tovey D; Ravaud P; Chaimani A; Boutron I
    Cochrane Database Syst Rev; 2023 Jun; 6(6):CD013881. PubMed ID: 37260086
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glutamine supplementation for critically ill adults.
    Tao KM; Li XQ; Yang LQ; Yu WF; Lu ZJ; Sun YM; Wu FX
    Cochrane Database Syst Rev; 2014 Sep; 2014(9):CD010050. PubMed ID: 25199493
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative Efficacy of Tocilizumab and Baricitinib Administration in COVID-19 Treatment: A Retrospective Cohort Study.
    Kojima Y; Nakakubo S; Takei N; Kamada K; Yamashita Y; Nakamura J; Matsumoto M; Horii H; Sato K; Shima H; Suzuki M; Konno S
    Medicina (Kaunas); 2022 Apr; 58(4):. PubMed ID: 35454352
    [No Abstract]   [Full Text] [Related]  

  • 34. Baricitinib Versus Tocilizumab for the Treatment of Moderate to Severe COVID-19.
    Reid NK; Joyner KR; Lewis-Wolfson TD
    Ann Pharmacother; 2023 Jul; 57(7):769-775. PubMed ID: 36314277
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of baricitinib for the treatment of moderate-to-severe atopic dermatitis: A systematic review and meta-analysis of randomized clinical trials.
    Wang B; Pan S; Yao Y; Zeng L; Zhang G
    Clin Exp Pharmacol Physiol; 2022 Nov; 49(11):1139-1149. PubMed ID: 35876397
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Baricitinib, a Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials.
    Kunwar S; Collins CE; Constantinescu F
    Clin Rheumatol; 2018 Oct; 37(10):2611-2620. PubMed ID: 30006916
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19.
    Bieber T; Feist E; Irvine AD; Harigai M; Haladyj E; Ball S; Deberdt W; Issa M; Grond S; Taylor PC
    Adv Ther; 2022 Nov; 39(11):4910-4960. PubMed ID: 36063279
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Novel Oral Antivirals in Hospitalized COVID-19 Patients: A Network Meta-Analysis of Randomized Clinical Trials.
    Liu H; Chen J; Shao W; Yan S; Ding S
    Clin Epidemiol; 2023; 15():1041-1053. PubMed ID: 37933389
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Baricitinib against severe COVID-19: effectiveness and safety in hospitalised pretreated patients.
    Iglesias Gómez R; Méndez R; Palanques-Pastor T; Ballesta-López O; Borrás Almenar C; Megías Vericat JE; López-Briz E; Font-Noguera I; Menéndez Villanueva R; Román Iborra JA; Poveda Andrés JL
    Eur J Hosp Pharm; 2022 Mar; 29(e1):e41-e45. PubMed ID: 34321249
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2).
    Kwon O; Senna MM; Sinclair R; Ito T; Dutronc Y; Lin CY; Yu G; Chiasserini C; McCollam J; Wu WS; King B
    Am J Clin Dermatol; 2023 May; 24(3):443-451. PubMed ID: 36855020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.